There's Plenty Of Good Science Out There: An Interview With AstraZeneca's Andrew Hughes (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
VC investors are starting to adopt a more big pharma mentality of waiting until a molecule really has proved itself before they put their money up, Hughes, AstraZeneca's global early development director for oncology, says.